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vember 19, 2013.he aim of this study was to assess the survival beneﬁt from heart transplantation (HT), deﬁned as reduction in
the risks for 90-day and 1-year mortality on undergoing HT close to listing, in candidates stratiﬁed by their risk
for waiting list mortality.Background Among patients listed for HT, those at higher risk for death without transplantation are also at higher risk for
early post-transplantation mortality.Methods All patients age 18 years listed for HT in the United States from 2007 to 2010 were analyzed. A model was
developed to predict the risk for waiting list mortality within 90 days, and listed patients were stratiﬁed into 10 risk
groups (deciles). All groups were followed for 1 year to assess cumulative 1-year mortality while on the waiting list.
Models of 90-day and 1-year post-transplantation mortality were developed using recipient data, and these risks
were estimated at listing in all listed candidates.Results Of 10,159 patients listed for HT, 596 (5.9%) died within 90 days and 1,054 (10.4%) within 1 year without
undergoing transplantation. Of 5,720 recipients of transplants with 1-year follow-up, 576 (10.1%) died within 1 year.
The risk for death while on the waiting list within 90 days increased from 1.6% to 19% across the 10 risk groups.
The survival beneﬁt from HT increased progressively with higher risk for death without transplantation (p< 0.001 for
trend), but there was no beneﬁt in the ﬁrst 6 risk groups.Conclusions The risk for waiting list mortality varies considerably among HT candidates. Although the survival beneﬁt of HT
generally increases with increasing risk for waiting list mortality, there is no measurable beneﬁt in many candidates
at the lower end of the risk spectrum. (J Am Coll Cardiol 2014;63:1169–78) ª 2014 by the American College of
Cardiology FoundationHeart transplantation (HT) is an established therapy for
end-stage heart failure (1,2). Although the number of
patients listed for HT in the United States continues to
increase, the supply of donor hearts remains relatively un-
changed (1,3). To minimize mortality in patients awaiting
HT, the U.S. allocation policy has prioritized sicker can-
didates to receive donor hearts since the early days of
transplantation (4,5). In the current 3-tier system, a patient, Boston Children’s Hospital, Boston, Massa-
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; revised manuscript received October 17, 2013,may be listed as status 2, 1B, or 1A on the basis of criteria
intended to represent increasing medical urgency. These
groups are then assigned progressively higher priority during
allocation (6). Because not all candidates listed at the highest
urgency status (1A) share a similar risk for death while
waiting, some experts have argued for a re-examination and
revision of the current allocation algorithm (7,8).See page 1179Previous studies have suggested that sicker patients among
those listed for HT are also at higher risk for post-
transplantation mortality (5). Although prioritizing donor
hearts to candidates on the basis of transplantation urgency is
justiﬁed as fairness or justice, whether it is also justiﬁable on
the basis of higher survival beneﬁt to such patients is unknown
(9,10). A better understanding of the relationship of the
survival beneﬁt fromHTwith increasing risk for death on the
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1170waiting list will be valuable not
only to the physicians caring for
patients with heart failure but also
to the allocation experts respon-
sible for reﬁning the heart allo-
cation algorithm.
We hypothesized that the
survival beneﬁt from HT esti-
mated at the time of listing will
be higher in patients at higherrisk for death while on the waiting list. The speciﬁc objec-
tives of this study were: 1) to risk-stratify patients listed for
HT on the basis of their risk for death without HT within
90 days of listing; and 2) to quantify the survival beneﬁt of
HT across risk strata of waiting list mortality.Methods
Study population. We identiﬁed all patients aged  18
years in the Organ Procurement and Transplantation
Network (OPTN) database listed for their ﬁrst HT in the
United States between January 1, 2007, and December 31,
2010. The OPTN database includes demographic and
clinical information at the time of listing in all HT candi-
dates and at the time of transplantation in all heart trans-
plant recipients in the United States, submitted by
transplantation centers. These data are supplemented with
death data in patients ever listed for HT (including for pa-
tients removed from the waiting list before undergoing HT)
from the Social Security Death Master File and are provided
to investigators as deidentiﬁed data. The Health Resources
and Services Administration of the U.S. Department of
Health and Human Services provides oversight of the ac-
tivities of the OPTN contractor, the United Network for
Organ Sharing (UNOS). We excluded patients who were
listed for heart retransplantation or multiple-organ trans-
plantation. Post-transplantation outcomes were analyzed in
study subjects who underwent HT between January 1, 2007
and March 1, 2011. This allowed us to analyze at least 1 year
of post-transplantation follow-up in all HT recipients.
Study design and deﬁnitions. The primary hypothesis was
that the survival beneﬁt from HT estimated at the time of
listing would be higher in patients who were at higher risk
for death without HT. Survival beneﬁt was quantiﬁed on the
basis of the estimated 90-day and 1-year risks for death
without HT and with HT after listing. We ﬁrst developed a
risk prediction model for 90-day waiting list mortality using
clinical data in listed patients and used this model to stratify
listed patients into 10 groups (approximate deciles) on the
basis of a progressively higher risk for death. We then
developed risk prediction models for 90-day and 1-year
post-transplantation mortality using clinical data at trans-
plantation in heart transplant recipients. We applied these
models to all listed patients at the time of listing and esti-
mated these risks in each of the 10 risk groups at listing.
Survival beneﬁt was quantiﬁed in each risk group as thereduction in risks for 90-day and 1-year mortality on un-
dergoing HT close to listing.
The primary endpoints were death without HT (while
listed or after removal from the list) and death after HT.
Demographic and clinical variables were deﬁned at listing to
develop themodel for deathwithoutHTand at transplantation
to develop models for death after HT. Race or ethnicity was
recorded as reported by the transplantation center and analyzed
as white (non-Hispanic white), black (non-Hispanic black),
Hispanic, or other. Renal function was analyzed as estimated
glomerular ﬁltration rate (ml/min/1.73 m2) using the Modi-
ﬁcation of Diet in Renal Disease formula (11,12).
None of the subjects had any missing data for the
following variables: age, sex, race or ethnicity, cardiac diag-
nosis, blood type, hemodynamic support (intra-aortic balloon
pump, inotrope support, ventilator, type of mechanical sup-
port), medical insurance (Medicaid), UNOS listing status,
dialysis, and the dates of listing, transplantation, death, or
removal from the waiting list. We imputed glomerular
ﬁltration rate values for patients with missing values at
listing (0.8%) or at transplantation (0.6%) using a multiple
imputation technique and clinical variables at listing and
transplantation, respectively.
Statistical analysis. Summary data are presented as median
(25th percentile, 75th percentile) or number (percent).
Waiting list outcomes in study patients were ﬁrst assessed
using competing outcomes analysis (13,14). Median waiting
list time, overall and by listing status, was estimated using
the Kaplan-Meier method. A multivariate logistic regression
model for 90-day mortality without HT was developed
using variables at listing retaining variables signiﬁcant at the
0.10 level on the basis of a likelihood ratio test. Model
discrimination was assessed using the area under the receiver-
operating characteristic curve (C-statistic) and calibration
using the Hosmer-Lemeshow goodness-of-ﬁt test. The
model was internally validated using a bootstrapping tech-
nique (200 random samples, 10,159 patients in each sample
with replacement). The model was used to quantify the
probability of death within 90 days in each listed patient by
applying model variables in that patient to the model. Listed
patients were stratiﬁed into 10 groups on the basis of
increasing risk for 90-day mortality without HT (approxi-
mate deciles). Observed cumulative 1-year mortality without
HT was assessed in each of the 10 risk groups.
We developed risk predictionmodels for 90-day and 1-year
post-transplantation mortality in heart transplant recipients
using logistic regression and variable values at transplantation.
We internally validated these models using bootstrapping, as
outlined previously. We used these models to quantify the
probability of 90-day and 1-year post-transplantation mor-
tality at the time of listing in each listed patient by applying
variable values at listing to the model. The survival beneﬁt
from HT at 90 days was calculated by subtracting the risk for
90-day post-transplantation mortality from the risk for
90-day mortality without HT in each risk group. Survival
beneﬁt at 1-year was calculated by subtracting the risk for
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11711-year post-transplantation mortality from observed 1-year
mortality in each risk group. Social factors such as race or
ethnicity, education, type of medical insurance, and regional
or center characteristics (such as center volume) were not
considered in the evaluation of survival beneﬁt and thus in
developing risk models.
Data were analyzed using SAS version 9.3 (SAS Institute
Inc., Cary, North Carolina). All statistical tests were
2-sided, and p values <0.05 were used to deﬁne statistical
signiﬁcance.Table 1 Baseline Characteristics of Patients at Lis
Variable
Dilated CMP
(n ¼ 4,773)
Ischem
(n ¼ 3
Age (yrs)
18–39 1,130 (24%) 112 (
40–59 2,529 (53%) 1,771 (
60–69 1,058 (22%) 1,699 (
70 56 (1.2%) 122 (
Men 3,253 (68%) 3,207 (
Blood type
A 1,691 (35%) 1,575 (
B 671 (14%) 452 (
O 2,215 (46%) 1,515 (
AB 196 (4.1%) 162 (
Listing status
1A 964 (20%) 804 (
1B 2,149 (45%) 1,315 (
2 1,660 (35%) 1,585 (
Diabetes
Type 1 116 (2.4%) 175 (
Type 2 897 (20%) 1,197 (
ICD 3,875 (81%) 2,938 (
PAP (mm Hg) (n ¼ 9,331) 31 (24, 38) 30 (
PWP (mm Hg) (n ¼ 8,964) 21 (15, 27) 20 (
Ventilation 91 (1.9%) 132 (
IABP 246 (5.2%) 258 (
Temporary support
ECMO 16 (0.3%) 18 (
Non-ECMO 19 (0.4%) 31 (
Durable support
Total artiﬁcial heart 26 (0.5%) 12 (
BIVAD 110 (2.3%) 93 (
Pulsatile LVAD 162 (3.4%) 178 (
Continuous-ﬂow LVAD 523 (11%) 396 (
Inotropes 1,770 (37%) 1,146 (
GFR category (ml/min/1.73 m2)
Dialysis 76 (1.6%) 62 (
<30 177 (3.7%) 146 (
30–60 1,795 (38%) 1,632 (
60 2,725 (57%) 1,864 (
Race/ethnicity
White 2,725 (57%) 2,953 (
Black 1,482 (31%) 382 (
Hispanic 412 (8.6%) 224 (
Other 154 (3.2%) 145 (
Values are n (%) or median (25th percentile, 75th percentile).
BIVAD ¼ biventricular assist device; CMP ¼ cardiomyopathy; ECMO ¼ extraco
intra-aortic balloon pump; ICD ¼ implantable cardiac deﬁbrillator; PAP ¼ pulmResults
Study population. During the study period, 10,754 pa-
tients age 18 years were listed for HT in the United
States. Of these, 273 patients were listed for multiple-organ
transplantation and 322 for heart retransplantation. The
remaining 10,159 patients formed the study cohort. Of
these, 4,773 (47%) had dilated cardiomyopathy and 3,704
(37%) had ischemic cardiomyopathy (see Table 1 for
baseline characteristics at listing). The median age of theting by Diagnosis
ic CMP
,704)
Other
(n ¼ 1,682)
Total
(n ¼ 10,159) p Value
<0.001
3.0%) 431 (26%) 1,673 (17%)
48%) 803 (48%) 5,103 (50%)
46%) 413 (25%) 3,170 (31%)
3.3%) 35 (2.1%) 213 (2.1%)
87%) 1,153 (69%) 7,613 (75%) <0.001
<0.001
43%) 667 (40%) 3,933 (39%)
12%) 202 (12%) 1,325 (13%)
41%) 752 (45%) 4,482 (44%)
4.4%) 61 (3.6%) 419 (4.1%)
<0.001
22%) 295 (18%) 2,063 (20%)
36%) 499 (30%) 3,963 (39%)
43%) 888 (53%) 4,133 (41%)
<0.001
4.7%) 36 (2.1%) 327 (3.2%)
32%) 246 (15%) 2,340 (23%)
79%) 1,066 (63%) 7,879 (78%) <0.001
23, 38) 29 (21, 36) 30 (23, 38) <0.001
14, 26) 20 (14, 25) 20 (15, 27) <0.001
3.6%) 40 (2.4%) 263 (2.6%) <0.001
7.0%) 79 (4.7%) 583 (5.7%) <0.001
<0.001
0.5%) 21 (1.2%) 55 (0.5%)
0.8%) 11 (0.7%) 61 (0.6%)
<0.001
0.3%) 8 (0.5%) 46 (0.5%)
2.5%) 39 (2.3%) 242 (2.4%)
4.8%) 58 (3.4%) 398 (3.9%)
11%) 90 (5.4%) 1,009 (9.9%)
31%) 459 (27%) 3,375 (33%) <0.001
<0.001
1.7%) 38 (2.3%) 176 (1.7%)
3.9%) 58 (3.4%) 381 (3.8%)
44%) 644 (38%) 4,071 (40%)
50%) 942 (56%) 5,531 (54%)
<0.001
80%) 1,272 (76%) 6,950 (68%)
10%) 223 (13%) 2,087 (21%)
6.0%) 126 (7.5%) 762 (7.5%)
3.9%) 61 (3.6%) 360 (3.5%)
rporeal membrane oxygenation; GFR ¼ glomerular ﬁltration rate; IABP ¼
onary artery pressure; PWP ¼ pulmonary artery wedge pressure.
Table 2
Risk Prediction Model for 90-Day Waiting List
Mortality*
Predictor Coefﬁcient Odds Ratio (95% CI)
Age at listing (reference: 18–59 yrs)
60–69 years 0.22 1.24 (1.0–1.5)
70 years 0.72 2.06 (1.3–3.3)
Restrictive CMP 0.78 2.17 (1.4–3.3)
Listing status (reference: status 2)
1A 1.17 3.22 (2.5–4.2)
1B 0.76 2.14 (1.7–2.7)
Ventilation 1.06 2.88 (2.0–4.1)
Intra-aortic balloon pump 0.52 1.67 (1.3–2.2)
Mechanical support (reference: none)
BIVAD or TAH 0.54 0.58 (0.3–1.0)
Continuous-ﬂow LVAD 0.77 0.46 (0.3–0.7)
Pulsatile LVAD 0.13 1.14 (0.8–1.7)
Temporary support 0.75 2.11 (1.3–3.4)
GFR (reference: 60 ml/min/1.73 m2)
30–59 ml/min/1.73 m2 0.46 1.58 (1.3–1.9)
<30 ml/min/1.73 m2 1.27 3.58 (2.6–4.9)
Dialysis 1.84 6.32 (4.2–9.4)
ICD 0.21 0.81 (0.7–1.0)
Intercept 3.77 d
*Includes death in patients who died after removal from the list but within 90 days of listing.
CI ¼ conﬁdence interval; TAH ¼ total artiﬁcial heart; other abbreviations as in Table 1.
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1172study cohort was 55 years, 20% were listed at the highest
urgency listing status (1A) (6), and 18% were receiving
mechanical support (including 2.4% with biventricular assist
devices, 14% with durable left ventricular assist devices
[LVADs], and 1.1% on temporary mechanical support).
Figure 1 illustrates competing outcomes during the ﬁrst
year after listing in the study cohort. Of 10,159 patients
listed for HT, 5,970 (59%) underwent HT, 1,054 (10.4%)
died without undergoing HT (695 deaths while on the
waiting list, 359 deaths after removal from the list), and
2,759 (27%) were still waiting for HT at 1 year. Of 1,054
deaths without HT, 328 (31%) deaths occurred within 30
days, 596 (57%) within 90 days, and 810 (77%) within 180
days of listing. The median waiting list time to HT was 78
days for the entire cohort, 26 days in patients listed as status
1A, 69 days in patients listed as status 1B, and 155 days
in patients listed as status 2. Post-transplantation outcomes
were analyzed in 5,720 heart transplant recipients with
1-year follow-up (see Online Table 1 for baseline charac-
teristics at transplantation). Of these, 576 patients (10.1%)
died within 1 year of transplantation.
Model for 90-day waiting list mortality. A multivariate
risk model for 90-day mortality without HT consisted of
7 risk factors (older age, diagnosis of restrictive cardiomy-
opathy, listing status 1A or 1B [6], ventilator support,
intra-aortic balloon pump, mechanical support, and renal
dysfunction) and 1 protective factor (presence of an
implantable cardiac deﬁbrillator) (Table 2). The overall
model was highly signiﬁcant (likelihood ratio chi-square ¼
427.2, Akaike information criterion ¼ 4,538.7). The
model’s ability to discriminate patients who died within
90 days from those who did not (C-statistic ¼ 0.73) and to
calibrate the risk for death (Hosmer-Lemeshow p ¼ 0.23;
see Online Figure 1 for predicted vs. observed 90-dayFigure 1 Competing Outcomes After Listing
Competing outcomes during the ﬁrst year after listing in patients listed for heart
transplantation in the United States.mortality among the 10 risk groups) were good. On inter-
nal validation by bootstrapping, the area under the receiver-
operating characteristic curve in repeated samples ranged
from 0.702 to 0.761 (mean 0.732; 95% conﬁdence interval:
0.731 to 0.734). On the basis of this model, the probability
of death within 90 days of listing without HT was calculated
as: p ¼ (X/Xþ 1), where X ¼ exp(intercept þ coefﬁcient for
each variable in Table 2 as it applies to the patient).
Using the model, the risk for 90-day mortality without
HT increased from 1.6% in the 1st risk group to 19% in the
10th risk group. Table 3 outlines the distribution of model
risk factors among the 10 risk groups. Patients in the lowest
2 risk groups were younger, were more likely to have dilated
or ischemic cardiomyopathy, were not supported on venti-
lators or balloon pumps, and had normal renal function at
listing. They were either not receiving any mechanical
support or were supported with continuous-ﬂow LVADs.
Patients in the 3rd and 4th risk groups tended to have
only 1 risk factor, such as older age or moderate renal
dysfunction. Patients in the 2 highest risk groups included
those with multiple risk factors, such as certain types of
mechanical support (temporary support, pulsatile LVAD, or
biventricular assist device), ventilator support, intra-aortic
balloon pump, and moderate or severe renal dysfunction
(Table 3).
Models for post-transplantation mortality. Risk predic-
tion models for post-transplantation 90-day mortality and
post-transplantation 1-year mortality are shown in Table 4.
Risk factors for post-transplantation 90-day mortality
included older age, a diagnosis of congenital heart disease,
restrictive or ischemic cardiomyopathy, ventilator support,
Table 3 Distribution of Risk Factors for Waiting List Mortality Among Risk Groups
Risk Factor
Waiting List Risk Group
1 2 3 4 5 6 7 8 9 10
Age (yrs)
18–59 1,387 (21%) 403 (5.9%) 939 (14%) 244 (3.6%) 959 (14%) 410 (6.1%) 962 (14%) 378 (5.6%) 531 (7.8%) 563 (8.3%)
60–69 26 (0.8%) 65 (2.1%) 560 (18%) 697 (22%) 6 (0.2%) 449 (14%) 124 (3.9%) 541 (17%) 351 (11%) 351 (11%)
70 0 (0%) 0 (0%) 1 (0.5%) 1 (0.5%) 24 (11%) 2 (0.9%) 58 (27%) 8 (3.8%) 34 (16%) 85 (40%)
Restrictive CMP 0 (0%) 1 (0.4%) 0 (0%) 0 (0%) 0 (0%) 28 (11%) 54 (21%) 9 (3.5%) 77 (30%) 89 (35%)
Listing status
1A 0 (0%) 0 (0%) 103 (5%) 96 (4.7%) 0 (0%) 115 (5.6%) 301 (15%) 283 (14%) 547 (27%) 618 (30%)
1B 197 (5%) 137 (3.5%) 131 (3.3%) 85 (2.1%) 954 (24%) 625 (16%) 731 (18%) 577 (15%) 201 (5.1%) 325 (8.2%)
2 1,216 (29%) 331 (8%) 1,266 (31%) 761 (18%) 35 (0.8%) 121 (2.9%) 112 (2.7%) 67 (1.6%) 168 (4.1%) 56 (1.4%)
Ventilator support 0 (0%) 0 (0%) 1 (0.4%) 1 (0.4%) 3 (1.1%) 1 (0.4%) 6 (2.3%) 7 (2.7%) 31 (12%) 213 (81%)
IABP 2 (0.3%) 1 (0.2%) 0 (0%) 15 (2.6%) 8 (1.4%) 14 (2.4%) 13 (2.2%) 27 (4.6%) 113 (19%) 390 (67%)
Mechanical support
Temporary support 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (0.9%) 2 (1.7%) 0 (0%) 1 (0.9%) 8 (6.9%) 104 (90%)
BIVAD or TAH 4 (1.6%) 3 (1.2%) 32 (13%) 26 (10%) 5 (2.0%) 60 (24%) 22 (8.7%) 30 (12%) 16 (6.3%) 54 (21%)
Pulsatile LVAD 0 (0%) 6 (1.7%) 3 (0.8%) 8 (2.2%) 0 (0%) 48 (13%) 39 (11%) 76 (21%) 106 (29%) 77 (21%)
Continuous LVAD 273 (27%) 142 (14%) 205 (20%) 158 (16%) 4 (0.4%) 80 (8.0%) 56 (5.6%) 20 (2.0%) 43 (4.3%) 25 (2.5%)
None of the above 1,136 (14%) 317 (3.8%) 1,260 (15%) 750 (8.9%) 979 (12%) 671 (8%) 1,027 (12%) 800 (9.5%) 743 (8.8%) 739 (8.8%)
GFR at listing (ml/min/1.73 m2)
Dialysis 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 45 (26%) 131 (74%)
<30 0 (0%) 0 (0%) 0 (0%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 0 (0%) 51 (13%) 81 (21%) 246 (65%)
30–59 22 (0.5%) 7 (0.2%) 809 (20%) 823 (20%) 5 (0.1%) 157 (3.9%) 745 (18%) 596 (15%) 522 (13%) 385 (9.5%)
60 1,391 (25%) 461 (8.3%) 691 (13%) 118 (2.1%) 983 (18%) 703 (13%) 399 (7.2%) 280 (5.1%) 268 (4.8%) 237 (4.3%)
ICD 1,393 (18%) 70 (0.9%) 1,392 (18%) 734 (9.3%) 986 (13%) 478 (6.1%) 995 (13%) 674 (8.6%) 594 (7.5%) 563 (7.1%)
Values are n (%).
Abbreviations as in Tables 1 and 2.
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Table 4 Risk Prediction Models for 90-Day and 1-Year Post-Transplantation Mortality
Predictor
Coefﬁcient
(90-Day Mortality)
Odds Ratio
(95% CI)
Coefﬁcient
(1-Year Mortality)
Odds Ratio
(95% CI)
Age (reference: 18–59 yrs)
60–69 yrs 0.48 1.6 (1.3–2.1) 0.37 1.45 (1.2–1.8)
70 yrs 0.46 1.6 (0.8–3.1) 0.31 1.36 (0.8–2.3)
Diagnosis
CHD 1.46 4.3 (2.4–7.7) 1.06 2.87 (1.7–4.8)
Ischemic CMP 0.37 1.5 (1.1–1.8) 0.28 1.32 (1.1–1.6)
Restrictive 0.73 2.1 (1.1–3.9) 0.93 2.54 (1.6–4.0)
Ventilation 0.90 2.5 (1.6–3.9) 0.63 1.88 (1.3–2.8)
Mechanical support (reference: none)
BIVAD or TAH 0.85 2.4 (1.5–3.6) 0.76 2.13 (1.5–3.0)
LVAD 0.45 1.6 (1.2 2.0) 0.36 1.43 (1.2–1.85)
ECMO 2.21 9.2 (4.6–18.1) 1.70 5.49 (2.9–10.5)
Non-ECMO temporary support 1.54 4.7 (1.8–11.9) 1.45 4.25 (1.9–9.5)
GFR (reference: 90 ml/min/1.73 m2)
30–59 ml/min/1.73 m2 0.41 1.5 (1.2–1.9) 0.29 1.34 (1.1–1.6)
<30 ml/min/1.73 m2 0.65 1.9 (1.1–3.3) 0.55 1.74 (1.1–2.7)
Dialysis 0.92 2.5 (1.4–4.4) 0.96 2.60 (1.7–4.0)
Intercept 3.69 – 2.86 –
Abbreviations as in Tables 1 and 2.
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1174mechanical support, and renal dysfunction at trans-
plantation. The overall model was highly signiﬁcant (like-
lihood ratio chi-square ¼ 141.3, Akaike information
criterion ¼ 2,530.9). The model’s ability to discriminate
survivors from nonsurvivors (C-statistic ¼ 0.67) and the
calibration between predicted and observed mortality
(Hosmer-Lemeshow p value ¼ 0.48; see Online Fig. 2 for
predicted vs. observed 90-day mortality among the 10 risk
groups) were good. Risk factors for post-transplantation
1-year mortality were similar to those for 90-day mortality
(Table 3). Although the model was highly signiﬁcant
(likelihood ratio chi-square ¼ 140.0, Akaike information
criterion ¼ 3,738.5), its performance was less robust
compared with the 90-day model (C-statistic ¼ 0.63,
Hosmer-Lemeshow p value ¼ 0.43) (Online Fig. 3).
Survival beneﬁt from HT at listing. Figure 2A illustrates
the risks for 90-day mortality without HT and 90-day
mortality after transplantation estimated at the time of
listing among the 10 risk groups. The survival beneﬁt from
HT at 90 days (percent reduction in risk for 90-day mor-
tality) (Fig. 2B) was negative or neutral in the lowest 6 risk
groups (risk for post-transplantation mortality higher or
similar to risk for waiting list mortality). Survival beneﬁt
increased from 1.2% in the 7th risk group to 8.5% in the
10th risk group (risk for waiting list mortality 19.5%, risk for
post-transplantation mortality 11%). Overall, the increase
in survival beneﬁt across the 10 risk groups was signiﬁcant
(p < 0.001 for trend).
Observed 1-year mortality without HT was 5.2% in
the lowest risk group and increased progressively to 26.7%
in the 10th risk group (Fig. 3A). The risk for 1-year
post-transplantation mortality at the time of listing was
higher or similar to the observed 1-year mortality (in percent)without HT in the ﬁrst 6 risk groups (Fig. 3A). Thus, there
was no 1-year survival beneﬁt from HT in the ﬁrst 6 risk
groups. Survival beneﬁt increased progressively between the
7th and 10th risk groups (Fig. 3B). For the entire cohort,
there was a signiﬁcant association of survival beneﬁt from HT
with increasing risk for death without HT (p < 0.001 for
trend).
Survival beneﬁt by listing status. The observed 90-day
mortality without HT was 3.2%, 6%, and 11% in patients
listed as UNOS listing statuses 2, 1B, and 1A, respectively.
The observed 1-year mortality without HT was 8.1%,
10.1%, and 14% in these groups, whereas the predicted
1-year post-HT mortality on undergoing HT close to listing
was 9.2%, 9.2%, and 10.8%, respectively. Thus, there was
no 1-year survival beneﬁt from HT in patients listed as
status 2 (1.1%), whereas status 1A patients derived higher
1-year survival beneﬁt (3.2%) than those listed as status 1B
(0.9%).
Discussion
This study had 3 major ﬁndings. First, the risk for death
within 90 days of listing varied by more than 10-fold among
patients listed for HT. Second, patients at higher risk for
death without HT were also at higher risk for post-
transplantation mortality. However, the risk for post-
transplantation mortality increased less sharply, so that
there was a higher survival beneﬁt from HT in sicker pa-
tients. Third, although the survival beneﬁt from HT
generally increased with increasing risk for waiting list
mortality, there was no measurable beneﬁt through 1 year
after transplantation in many candidates at the lower end of
the risk spectrum. These ﬁndings suggest that considering
Figure 2 Predicted Risks for 90-Day Mortality and Survival Beneﬁt Among the 10 Risk Groups
(A) Predicted risks for 90-day waiting list and 90-day post-transplantation mortality at listing for heart transplantation (HT) in patients with increasing risk for waiting list
mortality. (B) Survival beneﬁt associated with transplantation in these groups.
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listed patients in prioritizing heart allocation may improve
overall outcomes in patients listed for HT. Importantly,
these ﬁndings support the need for a re-examination and
revision of the current heart allocation algorithm in the
United States and suggest one possible approach.
Principles of organ allocation. Since the early days of
transplantation, the allocation of organs to listed patients has
been guided by the principles of justice or fairness and utility
or beneﬁt (4,9). After the publication of the ﬁnal rule in
1998 as a guide to U.S. allocation policy (10), medical ur-
gency became the primary determinant of allocation for all
organs. Allocation experts responsible for organ-speciﬁc al-
gorithms have applied this guide differently, however.
Whereas liver allografts are prioritized to patients with
higher scores on a scale that reﬂects the risk for waiting list
death within 90 days of listing (15), the allocation of hearts
was changed to a 3-tier system of medical urgency instead ofthe older 2-tier system (4). Although the current 3-tier
system prioritizes sicker candidates for heart allocation, our
analysis suggests that estimating the risk for 90-day mor-
tality using listing variables further improves their risk
stratiﬁcation. The ﬁnal rule also emphasized the importance
of avoiding futile transplantations, but only the lung allo-
cation algorithm considers expected post-transplantation
survival (and thus survival beneﬁt) at the time of listing in
a formal manner (16). The current analysis was inspired by
the current lung allocation approach in the United States.
The assessment of survival beneﬁt at the time of listing is an
essential step in calculating the lung allocation score and is
based on the projected 1-year survival on the waiting list
(without transplantation) and projected 1-year survival after
transplantation, assuming the patient were to receive lungs
with the listing characteristics or variables. Once listed, pa-
tients change their allocation scores only if the projected risk
on either side (on the waiting list or after transplantation)
Figure 3 1-Year Mortality Without and With HT and Survival Beneﬁt Among the 10 Risk Groups
(A) Observed 1-year waiting list mortality and predicted 1-year post-transplantation mortality at listing for heart transplantation (HT) in patient-groups with increasing risk
for waiting list mortality. (B) Survival beneﬁt associated with transplantation in these groups.
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1176has changed, not because of waiting list duration. Because
the survival beneﬁt from HT in the present study appeared
to be highest in patients most at risk for waiting list death,
reﬁning the current allocation algorithm such that it risk-
stratiﬁes patients better or considers survival beneﬁt will
likely prioritize similar candidates.
Although the major goals in revising the allocation are
to lower overall waiting list mortality and to improve access
to organs, the potential consequences for all patient
groups, including those that might be deprioritized by the
revision, are carefully assessed. How a revision will affect
resource utilization and costs is also an important consid-
eration. Once a patient is accepted as a candidate by atransplantation center, the overall costs of care include costs
while waiting and during the post-transplantation period.
Both components are higher, on average, for a higher-risk
patient compared with a lower-risk patient. Earlier trans-
plantations in higher-risk patients might lower their costs
and resource utilization during pre-transplantation care.
Whether the resulting savings will be sufﬁcient to balance
the increased system costs of post-transplantation care as
more hearts are directed to sicker candidates will require
further analysis.
Quantifying survival beneﬁt in listed patients. Several
quantitative approaches have been described to predict
1-year survival in patients with heart failure (17–20).
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medical therapy with the current post-transplantation out-
comes (1) is valuable in determining whether listing for HT
should be considered. The analysis of survival beneﬁt in the
present study is very different from such comparisons,
however, in that it was limited to patients already listed for
HT, was applied within the context of the present allocation
algorithm, and is much like the calculation of trans-
plantation beneﬁt at the time of listing in lung trans-
plantation candidates, which is then used to determine lung
allocation score (16). Our results illustrate that for many
patients listed for HT, the real risk for death on the waiting
list is not well captured by the present listing system. For
example, patients supported with continuous-ﬂow LVADs
without complications appear to be at low risk for death
without HT but may carry the same allocation priority as
patients receiving temporary mechanical support, patients on
ventilators, or those with diagnoses of restrictive cardiomy-
opathy who are often poor candidates for inotropes because
of their risk for arrhythmias and for mechanical support
because of technical challenges of LVAD implantation
related to space constraints in the ventricle (Table 3) (7,8).
These ﬁndings support the opinion that the current heart
allocation algorithm should be amended to stay true to the
spirit of the ﬁnal rule (7,8).
The models to predict the risks for death after listing
and in the post-transplantation period were both developed
within the study cohort because no such models exist
for patients on the waiting list. Furthermore, post-
transplantation outcomes have continued to improve in
recent years, and the study cohort consisted of very recent
patients (1,21,22). It is paramount while assessing survival
beneﬁt that the risk periods assessed be identical on the
post-listing and the post-transplantation side and that the
models consider only those variables that are available at
listing (16). We chose a 90-day period for risk stratiﬁcation
of listed patients because it accounted for a majority of
waiting list deaths and provided excellent risk stratiﬁcation
of HT candidates by identifying >10-fold variability in the
risk for death among groups. It may also be important that
it already forms the basis of allocation in another organ
(the liver) (15). Because calculating survival beneﬁt at
90 days is unsatisfactory because of the uncertainty of
subsequent post-transplantation survival, we also assessed
beneﬁt at 1 year, as is routinely done at the time of listing
in lung transplantation candidates. Our results suggest that
survival beneﬁt at 90 days is a good proxy for 1-year sur-
vival beneﬁt.
Study limitations. First, because this study was a retro-
spective analysis of a national database, there are potential
limitations related to data quality in such data sources. It
is notable, however, that data submission to UNOS is
mandatory at listing and at transplantation, and the sub-
mitted data are used for real-time heart allocation. Further-
more, these data are subject to periodic audits by UNOS
staff members and are also used for generating center-performance reports. Therefore, some safeguards of data
quality are to be expected.
Second, because only variables recorded at listing could be
used in evaluating survival beneﬁt, potential risk factors that
are currently not collected at listing, such as serum bilirubin
and human leukocyte antigen sensitization, cannot be
considered in assessing survival beneﬁt.
Third, we were able to assess transplantation beneﬁt only at
the time of listing. Because the variable values may change
after listing, whether the risk for death without trans-
plantation may be predicted equally well by applying new
variable values to the waiting list model or whether the addi-
tional knowledge of waiting list duration will improve such
predictions is unknown.We were unable to analyze the effect
of changes in patient states during the waiting list period
because the OPTN database lacks these details. Simulation
modeling or in-house analyses at UNOS may be able to
evaluate how the waiting duration and change in listing status
may alter these risks and the expected survival beneﬁt.
Finally, the estimated risk for waiting list mortality is
applicable only in the context of current heart allocation.
Any changes in policy that favor the allocation of hearts to
sicker patients may reduce their risk for waiting list mor-
tality. Therefore, periodic reappraisal of risk models for
waiting list and post-transplantation mortality will be
essential to keep such models current.
Conclusions
The risk for waiting list mortality varies considerably among
listed patients. Although survival beneﬁt from HT generally
increases with increasing risk for death while on the waiting
list, there is no beneﬁt through the ﬁrst post-transplantation
year in many candidates at the lower end of the risk
spectrum. More complex analyses should consider how the
waiting list duration and change in listing status may alter
these risks and the expected survival beneﬁt across the risk
spectrum. Considering the survival beneﬁt from HT during
heart allocation may improve overall outcomes in patients
listed for HT.
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APPENDIX
For supplemental ﬁgures and tables, please see the online version of this
article.
